Growth-adjusted reference values for the main pulmonary artery-to-ascending aorta ratio derived from clinically indicated chest CT in children - Summary - MDSpire
Advertisement
Growth-adjusted reference values for the main pulmonary artery-to-ascending aorta ratio derived from clinically indicated chest CT in children
To derive growth-adjusted reference values for the main pulmonary artery-to-ascending aorta ratio (MPA/AA) in pediatric patients and to assess their association with invasive hemodynamic data.
Approach:
Study Design: A retrospective multicenter study was conducted using data from two pediatric medical centers in China, involving a modeling cohort and an independent RHC cohort.
Cohort Selection: The modeling cohort included children under 18 years who underwent chest CT for various indications, excluding those with known pulmonary conditions. The independent RHC cohort included children who underwent right heart catheterization.
Image Acquisition: CT examinations were performed using different scanners and protocols, ensuring reliable measurement of MPA and AA.
Image Analysis: Measurements of MPA and AA were conducted by three board-certified pediatric radiologists following a standardized protocol.
Key Findings:
Growth-adjusted reference values for MPA/AA were established for pediatric patients.
The study confirmed the association of growth-adjusted MPA/AA values with invasive hemodynamic data from the RHC cohort.
Interpretation:
The derived reference values facilitate the interpretation of MPA/AA measurements in children, accounting for developmental changes.
Limitations:
The study was retrospective and conducted at two centers, which may limit generalizability.
Exclusion criteria may have led to selection bias, as certain conditions affecting pulmonary hemodynamics were not included.
Conclusion:
The study provides a framework for interpreting MPA/AA ratios in pediatric patients.
A recent Perspective offered a speculative mechanistic argument for acupuncture’s potential role as an adjunctive strategy in neuroinfectious diseases.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
